ChemicalBook > CAS DataBase List > Motavizumab
Motavizumab
- Product Name
- Motavizumab
- CAS No.
- 677010-34-3
- Chemical Name
- Motavizumab
- Synonyms
- Numax;MOTAVIZUMAB;Motavizumab (anti-RSV-F);Research Grade Motavizumab;Research Grade Motavizumab(DVV02803)
- CBNumber
- CB01509124
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Motavizumab Property
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
More
Less
N-Bromosuccinimide Price
American Custom Chemicals Corporation
- Product number
- ATB0010206
- Product name
- MOTAVIZUMAB
- Purity
- 98.00%
- Packaging
- 5MG
- Price
- $497.35
- Updated
- 2021/12/16
More
Less
Motavizumab Chemical Properties,Usage,Production
Uses
Motavizumab can prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease.
in vivo
Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice[1].
| Animal Model: | Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2[1] |
| Dosage: | 1.25 mg in 0.1 ml of PBS/per mouse |
| Administration: | Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once |
| Result: | Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice. |
Motavizumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Motavizumab Suppliers
- Tel
- 010-56205725
- Fax
- 010-65763397
- waley188@sohu.com
- Country
- China
- ProdList
- 12335
- Advantage
- 58
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 400-6206333 13167063860
- anhua.mao@aladdin-e.com
- Country
- China
- ProdList
- 48457
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 51288865780
- sales@biosynth.com
- Country
- China
- ProdList
- 6051
- Advantage
- 58
- Tel
- 400-668-6834
- info@selleck.cn
- Country
- China
- ProdList
- 6071
- Advantage
- 58
- Tel
- 9785721070
- info@cellsciences.com
- Country
- China
- ProdList
- 6308
- Advantage
- 58
- Tel
- +86-88938639 +86-17705817739
- info@dycnchem.com
- Country
- China
- ProdList
- 53899
- Advantage
- 58
- Tel
- 18818417021
- Country
- CHINA
- ProdList
- 127
- Advantage
- 58
- Tel
- 18666024416
- Country
- CHINA
- ProdList
- 185
- Advantage
- 58
- Tel
- 18312220236
- Country
- CHINA
- ProdList
- 178
- Advantage
- 58
- Tel
- --
- Fax
- --
- liujin1227@126.com
- Country
- China
- ProdList
- 414
- Advantage
- 30
677010-34-3, MotavizumabRelated Search:
Trastuzumab
Rituximab
Motavizumab
ibritumomab tiuxetan
palivizumab
Avelumab
Mirikizumab
Fulranumab
Uliledlimab
Research Grade Sofituzumab(DHJ31004)